Candidate drug targets for prevention or modification of epilepsy

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 229-247

  Varvel, Nicholas H ^a   Jiang, Jianxiong ^b   Dingledine, Raymond ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Anticonvulsant; Cytokines; Disease modification; Epileptogenesis; Neuroinflammation; Neuroprotection

Indexed keywords

ADENOSINE KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA CONVERTING ENZYME; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PROSTAGLANDIN E; PROSTAGLANDIN E2; PROSTANOID RECEPTOR; RESTRICTIVE ELEMENT 1; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; ANTICONVULSIVE AGENT;

ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN NERVE CELL; CHEMOPROPHYLAXIS; EPILEPSY; EPILEPTOGENESIS; HUMAN; MICROGLIA; NERVE CELL PLASTICITY; PRIORITY JOURNAL; REVIEW; SEIZURE; SEIZURE THRESHOLD; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; DRUG DEVELOPMENT; DRUG EFFECTS; ELECTROENCEPHALOGRAM; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ANTICONVULSANTS; BRAIN; BRAIN WAVES; DRUG DISCOVERY; EPILEPSY; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84920855917     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124607     Document Type: Review

References (139)

1. Wilson JV, Reynolds EH. 1990. Texts and documents: translation and analysis of a cuneiform text forming part of a Babylonian treatise on epilepsy. Med. Hist. 34:185-98
2. Todman D. 2008. Epilepsy in the Graeco-Roman world: Hippocratic medicine and Asklepian temple medicine compared. J. Hist. Neurosci. 17:435-41
3. Temkin NR. 2001. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: metaanalysis of controlled trials. Epilepsia 42:515-24
4. Loscher W, Brandt C. 2010. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol. Rev. 62:668-700
5. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, et al. 2005. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8:752-58
6. Nimmerjahn A, Kirchhoff F, Helmchen F. 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-18
7. Ransohoff RM, Cardona AE. 2010. The myeloid cells of the central nervous system parenchyma. Nature 468:253-62
8. Choi J, Nordli DR Jr, Alden TD, DiPatri A Jr, Laux L, et al. 2009. Cellular injury and neuroinflammation in children with chronic intractable epilepsy. J. Neuroinflamm. 6:38
9. Vezzani A, Granata T. 2005. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46:1724-43
10. Jorgensen MB, Finsen BR, Jensen MB, Castellano B, Diemer NH, Zimmer J. 1993. Microglial and astroglial reactions to ischemic and kainic acid-induced lesions of the adult rat hippocampus. Exp. Neurol. 120:70-88
11. Serrano GE, Lelutiu N, Rojas A, Cochi S, Shaw R, et al. 2011. Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J. Neurosci. 31:14850-60
12. Borges K, Gearing M, McDermott DL, Smith AB, Almonte AG, et al. 2003. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp. Neurol. 182:21-34
13. Jankowsky JL, Patterson PH. 2001. The role of cytokines and growth factors in seizures and their sequelae. Prog. Neurobiol. 63:125-49
14. Balosso S, Maroso M, Sanchez-Alavez M, Ravizza T, Frasca A, et al. 2008. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1?. Brain 131:3256-65
15. Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, et al. 2000. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Natl. Acad. Sci. USA 97:11534-39
16. Xiong ZQ, Qian W, Suzuki K, McNamara JO. 2003. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J. Neurosci. 23:955-60
17. Oliveira MS, Furian AF, Royes LF, Fighera MR, Fiorenza NG, et al. 2008. Cyclooxygenase-2/PGE2 pathway facilitates pentylenetetrazol-induced seizures. Epilepsy Res. 79:14-21
18. Galic MA, Riazi K, Pittman QJ. 2012. Cytokines and brain excitability. Front. Neuroendocrinol. 33:116-25
19. Obermeier B, Daneman R, Ransohoff RM. 2013. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19:1584-96
20. Librizzi L, Noe F, Vezzani A, de Curtis M, Ravizza T. 2012. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. Ann. Neurol. 72:82-90
21. Morin-Brureau M, Lebrun A, Rousset MC, Fagni L, Bockaert J, et al. 2011. Epileptiform activity induces vascular remodeling and zonula occludens 1 downregulation in organotypic hippocampal cultures: role of VEGF signaling pathways. J. Neurosci. 31:10677-88
22. Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, et al. 2012. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74:691-705
23. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, et al. 2007. The classical complement cascade mediates CNS synapse elimination. Cell 131:1164-78
24. Zhan Y, Paolicelli RC, Sforazzini F, Weinhard L, Bolasco G, et al. 2014. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat. Neurosci. 17:400-6
25. Trapp BD, Wujek JR, Criste GA, Jalabi W, Yin X, et al. 2007. Evidence for synaptic stripping by cortical microglia. Glia 55:360-68
26. Stephan AH, Barres BA, Stevens B. 2012. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 35:369-89
27. Wetherington J, Serrano G, Dingledine R. 2008. Astrocytes in the epileptic brain. Neuron 58:168-78
28. Amiry-Moghaddam M, Ottersen OP. 2003. The molecular basis of water transport in the brain. Nat. Rev. Neurosci. 4:991-1001
29. Manley GT, Fujimura M, Ma T, Noshita N, Filiz F, et al. 2000. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat. Med. 6:159-63
30. Djukic B, Casper KB, Philpot BD, Chin LS, McCarthy KD. 2007. Conditional knock-out of Kir4. 1 leads to glial membrane depolarization, inhibition of potassium and glutamate uptake, and enhanced short-term synaptic potentiation. J. Neurosci. 27:11354-65
31. Kucheryavykh YV, Kucheryavykh LY, Nichols CG, Maldonado HM, Baksi K, et al. 2007. Downregulation of Kir4. 1 inward rectifying potassium channel subunits by RNAi impairs potassium transfer and glutamate uptake by cultured cortical astrocytes. Glia 55:274-81
32. Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC. 1995. Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J. Neurosci. 15:1835-53
33. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, et al. 1994. Localization of neuronal and glial glutamate transporters. Neuron 13:713-25
34. Danbolt NC. 2001. Glutamate uptake. Prog. Neurobiol. 65:1-105
35. Proper EA, Hoogland G, Kappen SM, Jansen GH, Rensen MG, et al. 2002. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 125:32-43
36. Eid T, Thomas MJ, Spencer DD, Runden-Pran E, Lai JC, et al. 2004. Loss of glutamine synthetase in the human epileptogenic hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy. Lancet 363:28-37
37. Tessler S, Danbolt NC, Faull RL, Storm-Mathisen J, Emson PC. 1999. Expression of the glutamate transporters in human temporal lobe epilepsy. Neuroscience 88:1083-91
38. Scharfman HE. 2002. Epilepsy as an example of neural plasticity. Neuroscientist 8:154-73
39. Mathern GW, Babb TL, Micevych PE, Blanco CE, Pretorius JK. 1997. Granule cell mRNA levels for BDNF, NGF, and NT-3 correlate with neuron losses or supragranular mossy fiber sprouting in the chronically damaged and epileptic human hippocampus. Mol. Chem. Neuropathol. 30:53-76
40. Boulle F, Kenis G, Cazorla M, Hamon M, Steinbusch HW, et al. 2012. TrkB inhibition as a therapeutic target for CNS-related disorders. Prog. Neurobiol. 98:197-206
41. Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, et al. 2009. Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc. Natl. Acad. Sci. USA 106:7191-96
42. Liu G, Gu B, He XP, Joshi RB, Wackerle HD, et al. 2013. Transient inhibition of TrkB kinase after status epilepticus prevents development of temporal lobe epilepsy. Neuron 79:31-38
43. Brooks-Kayal AR, Shumate MD, Jin H, Rikhter TY, Coulter DA. 1998. Selective changes in single cell GABAA receptor subunit expression and function in temporal lobe epilepsy. Nat. Med. 4:1166-72
44. Peng Z, Huang CS, Stell BM, Mody I, Houser CR. 2004. Altered expression of the δ subunit of the GABAA receptor in a mouse model of temporal lobe epilepsy. J. Neurosci. 24:8629-39
45. Zhang N, Wei W, Mody I, Houser CR. 2007. Altered localization of GABAA receptor subunits on dentate granule cell dendrites influences tonic and phasic inhibition in a mouse model of epilepsy. J. Neurosci. 27:7520-31
46. Tauck DL, Nadler JV. 1985. Evidence of functional mossy fiber sprouting in hippocampal formation of kainic acid-treated rats. J. Neurosci. 5:1016-22
47. Cavazos JE, Golarai G, Sutula TP. 1991. Mossy fiber synaptic reorganization induced by kindling: time course of development, progression, and permanence. J. Neurosci. 11:2795-803
48. Nadler JV, Perry BW, Cotman CW. 1980. Selective reinnervation of hippocampal area CA1 and the fascia dentata after destruction of CA3-CA4 afferents with kainic acid. Brain Res. 182:1-9
49. Babb TL, Kupfer WR, Pretorius JK, Crandall PH, Levesque MF. 1991. Synaptic reorganization by mossy fibers in human epileptic fascia dentata. Neuroscience 42:351-63
50. Houser CR, Miyashiro JE, Swartz BE, Walsh GO, Rich JR, Delgado-Escueta AV. 1990. Altered patterns of dynorphin immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy. J. Neurosci. 10:267-82
51. Sutula T, Cascino G, Cavazos J, Parada I, Ramirez L. 1989. Mossy fiber synaptic reorganization in the epileptic human temporal lobe. Ann. Neurol. 26:321-30
52. Kotti T, Riekkinen PJ Sr, Miettinen R. 1997. Characterization of target cells for aberrant mossy fiber collaterals in the dentate gyrus of epileptic rat. Exp. Neurol. 146:323-30
53. Okazaki MM, Evenson DA, Nadler JV. 1995. Hippocampal mossy fiber sprouting and synapse formation after status epilepticus in rats: visualization after retrograde transport of biocytin. J. Comp. Neurol. 352:515-34
54. Wenzel HJ, Woolley CS, Robbins CA, Schwartzkroin PA. 2000. Kainic acid-induced mossy fiber sprouting and synapse formation in the dentate gyrus of rats. Hippocampus 10:244-60
55. Zhang N, Houser CR. 1999. Ultrastructural localization of dynorphin in the dentate gyrus in human temporal lobe epilepsy: A study of reorganized mossy fiber synapses. J. Comp. Neurol. 405:472-90
56. Okazaki MM, Molnar P, Nadler JV. 1999. Recurrent mossy fiber pathway in rat dentate gyrus: synaptic currents evoked in presence and absence of seizure-induced growth. J. Neurophysiol. 81:1645-60
57. Wuarin JP, Dudek FE. 1996. Electrographic seizures and new recurrent excitatory circuits in the dentate gyrus of hippocampal slices from kainate-treated epileptic rats. J. Neurosci. 16:4438-48
58. Sloviter RS. 1992. Possible functional consequences of synaptic reorganization in the dentate gyrus of kainate-treated rats. Neurosci. Lett. 137:91-96
59. Mathern GW, Bertram EH III, Babb TL, Pretorius JK, Kuhlman PA, et al. 1997. In contrast to kindled seizures, the frequency of spontaneous epilepsy in the limbic statusmodel correlates with greater aberrant fascia dentata excitatory and inhibitory axon sprouting, and increased staining for N-methyl-D-aspartate, AMPA and GABAA receptors. Neuroscience 77:1003-19
60. Mathern GW, Cifuentes F, Leite JP, Pretorius JK, Babb TL. 1993. Hippocampal EEG excitability and chronic spontaneous seizures are associated with aberrant synaptic reorganization in the rat intrahippocampal kainate model. Electroencephalogr. Clin. Neurophysiol. 87:326-39
61. Lemos T, Cavalheiro EA. 1995. Suppression of pilocarpine-induced status epilepticus and the late development of epilepsy in rats. Exp. Brain Res. 102:423-28
62. Masukawa LM, Uruno K, Sperling M, OConnor MJ, Burdette LJ. 1992. The functional relationship between antidromically evoked field responses of the dentate gyrus and mossy fiber reorganization in temporal lobe epileptic patients. Brain Res. 579:119-27
63. Heng K, Haney MM, Buckmaster PS. 2013. High-dose rapamycin blocks mossy fiber sprouting but not seizures in a mouse model of temporal lobe epilepsy. Epilepsia 54:1535-41
64. Zlokovic BV. 2008. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178-201
65. Fieschi C, Lenzi GL, Zanette E, Orzi F, Passero S. 1980. Effects on EEG of the osmotic opening of the blood-brain barrier in rats. Life Sci. 27:239-43
66. Marchi N, Angelov L, Masaryk T, Fazio V, Granata T, et al. 2007. Seizure-promoting effect of bloodbrain barrier disruption. Epilepsia 48:732-42
67. Ivens S, Kaufer D, Flores LP, Bechmann I, Zumsteg D, et al. 2007. TGF-βreceptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 130:535-47
68. Cacheaux LP, Ivens S, David Y, Lakhter AJ, Bar-Klein G, et al. 2009. Transcriptome profiling reveals TGF-βsignaling involvement in epileptogenesis. J. Neurosci. 29:8927-35
69. Fabene PF, Navarro Mora G, Martinello M, Rossi B, Merigo F, et al. 2008. A role for leukocyteendothelial adhesion mechanisms in epilepsy. Nat. Med. 14:1377-83
70. Agarwal S, Hartz AM, Elmquist WF, Bauer B. 2011. Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up. Curr. Pharm. Des. 17:2793-802
71. Loscher W, Potschka H. 2005. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6:591-602
72. Avemary J, Salvamoser JD, Peraud A, Remi J, Noachtar S, et al. 2013. Dynamic regulation of Pglycoprotein in human brain capillaries. Mol. Pharm. 10:3333-41
73. van Vliet EA, Zibell G, Pekcec A, Schlichtiger J, Edelbroek PM, et al. 2010. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 58:404-12
74. Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, Vezzani A. 2008. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol. Dis. 29:142-60
75. Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. 2013. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proc. Natl. Acad. Sci. USA 110:3591-96
76. Sayyah M, Javad-Pour M, Ghazi-Khansari M. 2003. The bacterial endotoxin lipopolysaccharide enhances seizure susceptibility in mice: involvement of proinflammatory factors: nitric oxide and prostaglandins. Neuroscience 122:1073-80
77. Dinarello CA. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16:457-99
78. Ravizza T, Vezzani A. 2006. Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. Neuroscience 137:301-8
79. Vezzani A, French J, Bartfai T, Baram TZ. 2011. The role of inflammation in epilepsy. Nat. Rev. Neurol. 7:31-40
80. Dube C, Vezzani A, Behrens M, Bartfai T, Baram TZ. 2005. Interleukin-1β contributes to the generation of experimental febrile seizures. Ann. Neurol. 57:152-55
81. Dube CM, Ravizza T, Hamamura M, Zha Q, Keebaugh A, et al. 2010. Epileptogenesis provoked by prolonged experimental febrile seizures: mechanisms and biomarkers. J. Neurosci. 30:7484-94
82. De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, et al. 2000. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur. J. Neurosci. 12:2623-33
83. Maroso M, Balosso S, Ravizza T, Iori V, Wright CI, et al. 2011. Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice. Neurotherapeutics 8:304-15
84. Jung KH, Chu K, Lee ST, Kim J, Sinn DI, et al. 2006. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 23:237-46
85. Polascheck N, Bankstahl M, Loscher W. 2010. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp. Neurol. 224:219-33
86. McCullough L, Wu L, Haughey N, Liang X, Hand T, et al. 2004. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24:257-68
87. Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, et al. 2010. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc. Natl. Acad. Sci. USA 107:2307-12
88. Savonenko A, Munoz P, Melnikova T, Wang Q, Liang X, et al. 2009. Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor. Exp. Neurol. 217:63-73
89. Yang H, Zhang J, Breyer RM, Chen C. 2009. Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J. Neurochem. 108:295-304
90. Liang X, Wang Q, Hand T, Wu L, Breyer RM, et al. 2005. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimers disease. J. Neurosci. 25:10180-87
91. Liang X, Wang Q, Shi J, Lokteva L, Breyer RM, et al. 2008. The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in amodel of amyotrophic lateral sclerosis. Ann. Neurol. 64:304-14
92. Quan Y, Jiang J, Dingledine R. 2013. EP2 receptor signaling pathways regulate classical activation of microglia. J. Biol. Chem. 288:9293-302
93. Jin J, Shie FS, Liu J, Wang Y, Davis J, et al. 2007. Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated α-Synuclein. J. Neuroinflamm. 4:2
94. Jiang J, Ganesh T, Du Y, Quan Y, Serrano G, et al. 2012. Small molecule antagonist reveals seizureinduced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc. Natl. Acad. Sci. USA 109:3149-54
95. Boison D. 2012. Adenosine dysfunction in epilepsy. Glia 60:1234-43
96. Lovatt D, Xu Q, Liu W, Takano T, Smith NA, et al. 2012. Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc. Natl. Acad. Sci. USA 109:6265-70
97. Boison D, Chen JF, Fredholm BB. 2010. Adenosine signaling and function in glial cells. Cell Death Differ. 17:1071-82
98. Szybala C, Pritchard EM, Lusardi TA, Li T, Wilz A, et al. 2009. Antiepileptic effects of silk-polymer based adenosine release in kindled rats. Exp. Neurol. 219:126-35
99. Li T, Ren G, Lusardi T, Wilz A, Lan JQ, et al. 2008. Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J. Clin. Invest. 118:571-82
100. Gouder N, Scheurer L, Fritschy JM, Boison D. 2004. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J. Neurosci. 24:692-701
101. Williams-Karnesky RL, Sandau US, Lusardi TA, Lytle NK, Farrell JM, et al. 2013. Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis. J. Clin. Invest. 123:3552-63
102. Boison D. 2013. Adenosine kinase: exploitation for therapeutic gain. Pharmacol. Rev. 65:906-43
103. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, et al. 2013. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann. Neurol. 74:679-87
104. Sunnen CN, Brewster AL, Lugo JN, Vanegas F, Turcios E, et al. 2011. Inhibition of themammalian target of rapamycin blocks epilepsy progression in NS-Pten conditional knockout mice. Epilepsia 52:2065-75
105. Huang X, Zhang H, Yang J, Wu J, McMahon J, et al. 2010. Pharmacological inhibition of themammalian target of rapamycin pathway suppresses acquired epilepsy. Neurobiol. Dis. 40:193-99
106. Zeng LH, Rensing NR, Wong M. 2009. Themammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci. 29:6964-72
107. Minichiello L. 2009. TrkB signalling pathways in LTP and learning. Nat. Rev. Neurosci. 10:850-60
108. Wyneken U, Smalla KH, Marengo JJ, Soto D, de la Cerda A, et al. 2001. Kainate-induced seizures alter protein composition and N-methyl-D-aspartate receptor function of rat forebrain postsynaptic densities. Neuroscience 102:65-74
109. Takahashi M, Hayashi S, Kakita A, Wakabayashi K, Fukuda M, et al. 1999. Patients with temporal lobe epilepsy show an increase in brain-derived neurotrophic factor protein and its correlation with neuropeptide Y. Brain Res. 818:579-82
110. Xu B, Michalski B, Racine RJ, Fahnestock M. 2004. The effects of brain-derived neurotrophic factor (BDNF) administration on kindling induction, Trk expression and seizure-related morphological changes. Neuroscience 126:521-31
111. He XP, Minichiello L, Klein R, McNamara JO. 2002. Immunohistochemical evidence of seizure-induced activation of trkB receptors in themossy fiber pathway of adultmouse hippocampus. J. Neurosci. 22:7502-8
112. Binder DK, Routbort MJ, Ryan TE, Yancopoulos GD, McNamara JO. 1999. Selective inhibition of kindling development by intraventricular administration of TrkB receptor body. J. Neurosci. 19:1424-36
113. He XP, Kotloski R, Nef S, Luikart BW, Parada LF, McNamara JO. 2004. Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron 43:31-42
114. He XP, Pan E, Sciarretta C, Minichiello L, McNamara JO. 2010. Disruption of TrkB-mediated phospholipase Csignaling inhibits limbic epileptogenesis. J. Neurosci. 30:6188-96
115. Rawlings JS, Rosler KM, Harrison DA. 2004. The JAK/STAT signaling pathway. J. Cell Sci. 117:1281-83
116. Lund IV, Hu Y, Raol YH, Benham RS, Faris R, et al. 2008. BDNF selectively regulates GABAA receptor transcription by activation of the JAK/STAT pathway. Sci. Signal. 1:ra9
117. Murray PJ. 2007. The JAK-STAT signaling pathway: input and output integration. J. Immunol. 178:2623-29
118. Xu Z, Xue T, Zhang Z, Wang X, Xu P, et al. 2011. Role of signal transducer and activator of transcription- 3 in up-regulation of GFAP after epilepsy. Neurochem. Res. 36:2208-15
119. Oliva AA Jr, Kang Y, Sanchez-Molano J, Furones C, Atkins CM. 2012. STAT3 signaling after traumatic brain injury. J. Neurochem. 120:710-20
120. Bolli R, Stein AB, Guo Y, Wang OL, Rokosh G, et al. 2011. Amurinemodel of inducible, cardiac-specific deletion of STAT3: its use to determine the role of STAT3 in the upregulation of cardioprotective proteins by ischemic preconditioning. J. Mol. Cell. Cardiol. 50:589-97
121. Grabenstatter HL, Del Angel YC, Carlsen J, Wempe MF, White AM, et al. 2014. The effect of STAT3 inhibition on status epilepticus and subsequent spontaneous seizures in the pilocarpine model of acquired epilepsy. Neurobiol. Dis. 62:73-85
122. Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor β in human disease. N. Engl. J. Med. 342:1350-58
123. Heinemann U, Kaufer D, Friedman A. 2012. Blood-brain barrier dysfunction, TGFβ signaling, and astrocyte dysfunction in epilepsy. Glia 60:1251-57
124. Wajant H, Pfizenmaier K, Scheurich P. 2003. Tumor necrosis factor signaling. Cell Death Differ. 10:45-65
125. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. 1999. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17:331-67
126. McCoy MK, Tansey MG. 2008. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflamm. 5:45
127. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. 1992. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:323-29
128. Balosso S, Ravizza T, Perego C, Peschon J, Campbell IL, et al. 2005. Tumor necrosis factor-αinhibits seizures in mice via p75 receptors. Ann. Neurol. 57:804-12
129. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. 1997. Astrocyte-specific but not neuron-specific transmembraneTNFtriggers inflammation and degeneration in the central nervous system of transgenic mice. J. Immunol. 158:438-45
130. Yuhas Y, Weizman A, Ashkenazi S. 2003. Bidirectional concentration-dependent effects of tumor necrosis factor alpha in Shigella dysenteriae-related seizures. Infect. Immun. 71:2288-91
131. Fischer R, Maier O, Siegemund M, Wajant H, Scheurich P, Pfizenmaier K. 2011. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLOS ONE 6:e27621
132. Kitagaki M, Isoda K, Kamada H, Kobayashi T, Tsunoda S, et al. 2012. Novel TNF-β receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice. J. Atheroscler. Thromb. 19:36-46
133. Strahl BD, Allis CD. 2000. The language of covalent histone modifications. Nature 403:41-45
134. Johnson DS, Mortazavi A, Myers RM, Wold B. 2007. Genome-wide mapping of in vivo protein-DNA interactions. Science 316:1497-502
135. Roopra A, Dingledine R, Hsieh J. 2012. Epigenetics and epilepsy. Epilepsia 53(Suppl. 9):2-10
136. Jessberger S, Nakashima K, Clemenson GD Jr, Mejia E, Mathews E, et al. 2007. Epigenetic modulation of seizure-induced neurogenesis and cognitive decline. J. Neurosci. 27:5967-75
137. Palm K, Belluardo N, Metsis M, Timmusk T. 1998. Neuronal expression of zinc finger transcription factor REST/NRSF/XBR gene. J. Neurosci. 18:1280-96
138. Santoro B, Lee JY, Englot DJ, Gildersleeve S, Piskorowski RA, et al. 2010. Increased seizure severity and seizure-related death in mice lacking HCN1 channels. Epilepsia 51:1624-27
139. McClelland S, Flynn C, Dube C, Richichi C, Zha Q, et al. 2011. Neuron-restrictive silencer factormediated hyperpolarization-activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy. Ann. Neurol. 70:454-64